Resources Repository
-
ReportPublication 2016Cost-Effectiveness of Mental, Neurological, and Substance Use Disorders
This report chapter reviews the available cost-effectiveness evidence for the different levels and underpinning strategies of …
This report chapter reviews the available cost-effectiveness evidence for the different levels and underpinning strategies of the mental health care system, with a focus on information generated in or for lower and middle income countries. First, the chapter reviews the economic evidence for mental health prevention and protection at the population and community levels of the health and welfare system, including legislative, regulatory, and informational measures at the public policy level (population platform), as well as…
Evidence Synthesis | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Health Systems | Health/Medicine -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Global | Infectious Diseases | Economics/Finance | Health/Medicine -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | North America | Preferences/Values | Infectious Diseases | Policy/Regulation | Government/Law -
ReportPublication 2019Reference Case Guidelines for BCA in Global Health and Development
The “Benefit‐Cost Analysis Reference Case: Principles, Methods, and Standards” project, with support from the Bill …
The “Benefit‐Cost Analysis Reference Case: Principles, Methods, and Standards” project, with support from the Bill & Melinda Gates Foundation, culminated in the “Reference Case Guidelines for Benefit-Cost Analysis in Global Health and Development.” These guidelines aim to facilitate the utilization and increase the effectiveness of benefit-cost analysis by clarifying essential concepts, aiding implementation, and suggesting default values for key parameters, along with options for standardized sensitivity analysis. Targeted at practitioners with economic evaluation expertise across…
Benefit-Cost Analysis | Global | Health/Medicine -
ReportPublication 2019Top 10 Health Economics and Outcomes Research Trends
As governments and other payers struggle with provision of the best possible health outcomes at …
As governments and other payers struggle with provision of the best possible health outcomes at affordable costs, the field of health economics and outcomes research (HEOR) has experienced rapid growth. The International Society for Pharmacoeconomics Outcomes Research (ISPOR) produced the ISPOR 2019 Top 10 HEOR Trends which serves to outline the top 10 that the Society members identified that will be the most impactful during 2019. Development of this report included a comprehensive review and…
Global | Health Outcomes | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Health/Medicine | Science/Technology -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Evidence Synthesis | North America | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
ReportPublication 2015Chapter 4: Cervical Cancer
This chapter focuses on the possibility of primary prevention of cervical cancer as a result …
This chapter focuses on the possibility of primary prevention of cervical cancer as a result of the introduction of two commercially available vaccines against human papillomavirus (HPV). Few low- and middle-income countries (LMICs) have initiated or sustained cytology-based cervical cancer prevention programs, and these countries experience very high incidence and mortality rates. Fortunately, alternative strategies to prevent cervical cancer have been investigated and extensively evaluated in these settings. The authors report findings from cost-effectiveness analyses…
Cost-Effectiveness Analysis | Global | Mathematical Models | Infectious Diseases | Chronic Disease/Risk | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ReportPublication 2003ISPOR Task Force Report: Good Practice for Decision Analytic Modeling in Health-Care
This report describes the consensus of a task force convened to provide modelers with guidelines …
This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies. While published more than a decade ago, it remains a clearly written resource for thinking about how to accurately describe the components of models and their quality. Criteria for assessing the quality of models fell into three areas: model structure, data used as inputs to models, and model validation. Several major themes cut across…
Calibration/Validation | Global | Mathematical Models | Health/Medicine | Science/Technology